Please login to the form below

Not currently logged in
Email:
Password:

haematological cancer

This page shows the latest haematological cancer news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts haematology pipeline with $7bn Impact Bio deal

Celgene boosts haematology pipeline with $7bn Impact Bio deal

and downgraded sales estimates for its haematological cancer drugs.

Latest news

  • The Harmony Alliance gathers to battle blood cancer

    nd. general assembly based in Berlin, Germany last week, 120 representatives from the Innovative Medicines Initiative’s ( IMI) Harmony Alliance all gathered to discuss achievements and objectives surrounding blood cancer. ... Michel Van Speybroeck,

  • AbbVie and Roche plan Venclexta combo filings in leukaemia AbbVie and Roche plan Venclexta combo filings in leukaemia

    Meanwhile, AbbVie is also looking at combining Venclexta with its flagship cancer drug, BTK inhibitor Imbruvica (ibrutinib) for haematological cancer, which has already hit the blockbuster mark with sales topping

  • Intriguing data with Juno's new CAR-T therapy Intriguing data with Juno's new CAR-T therapy

    Suggests a long treatment effect from the biotech's JCAR017 candidate. CAR-T developer Juno Therapeutics has reported data suggesting the benefits of this type of cancer immunotherapy could extend long ... haematological cancer followed by JCAR017 - an

  • Celgene joins PD-1 race via partnership with BeiGene Celgene joins PD-1 race via partnership with BeiGene

    The deal for the drug - which is in late-stage trials in cancer and has been tested in around 500 patients to date - gives haematological cancer specialist Celgene a bigger pipeline ... It is a great deal for BeiGene because it gives it a fast-track into

  • Takeda's gamble on Ariad pays off with Alunbrig approval Takeda's gamble on Ariad pays off with Alunbrig approval

    After an accelerated review Alunbrig (brigatinib) has been given a green light as a second-line treatment for ALK-positive, non-small cell lung cancer (NSCLC) after first-line therapy with ... Takeda agreed to buy Ariad earlier this year in a $5.2bn deal,

More from news
Approximately 2 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological malignancies. ... Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics